Advertisement

Quality of Life Assessments in the Development and Clinical Trials of New Antipsychotics: Pharmaceutical Industry Perspective

  • Raimund BullerEmail author
  • Christophe Sapin
Chapter
  • 604 Downloads

Abstract

Quality of life (QoL) assessments illustrate the patients’ subjective views and needs and can play a key role in drug development of treatments for schizophrenia. So far, QoL data from trials with antipsychotics are mainly used for commercial and promotional purposes or for negotiations on pricing and reimbursement. In the future, a greater focus on QoL could change the development process and guide research for the next generation of treatments, since these will have to significantly improve outcomes and not simply reduce symptoms or re-hospitalization rates. The chapter identifies important aspects of methodology with regard to the selection and use of QoL assessments in drug development. So far, there are no universally accepted operational definition of QoL and no “gold standard” instrument. Based on a variety of theoretical constructs that cover general and disease-specific aspects of health-related quality of life (HRQL), there is a suitable choice of assessment tools with adequate psychometric properties. Cautious selection according to the specific aims of a trial and a sensible integration into clinical programs can help uncover crucial properties of treatments that are vital for reaching ambitious goals like recovery from the illness. However, besides treatment, QoL assessments are also influenced by illness-related and other factors, which need to be considered judiciously to draw valid conclusions from trials. It is now evident that a vast majority of patients with schizophrenia can provide relevant information on HRQL. Regulatory authorities have declared their willingness to review claims based on QoL data and are providing guidance documents to sponsors for this purpose, which can also apply to schizophrenia.

Keywords

Negative Symptom European Medicine Agency HRQL Change Neuroleptic Dysphoria European Medicine Agency Reflection Paper 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Al Sayah F, Ishaque S, Lau D, Johnson JA. Health related quality of life measures in Arabic speaking populations: a systematic review on cross-cultural adaptation and measurement properties. Qual Life Res. 2013;22:213–29.CrossRefPubMedGoogle Scholar
  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.Google Scholar
  3. Andreasen N, Carpenter W, Kane J, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441–9.CrossRefPubMedGoogle Scholar
  4. Andresen R, Oades L, Caputi P. The experience of recovery from schizophrenia: towards an empirically validated stage model. Aust N Z J Psychiatry. 2003;37:586–94.CrossRefPubMedGoogle Scholar
  5. Auquier P, Simeoni MC, Sapin C, Reine G, Aghababian V, Cramer J, Lancon C. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL. Schizophr Res. 2003;63:137–49.CrossRefPubMedGoogle Scholar
  6. Awad AG, Voruganti LNP. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18:877–93.CrossRefPubMedGoogle Scholar
  7. Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia – an update. Pharmacoeconomics. 2012;30:183–95.CrossRefPubMedGoogle Scholar
  8. Awad AG, Voruganti LNP, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 1997;6:21–36.CrossRefPubMedGoogle Scholar
  9. Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. Leipzig/Wien: Franz Deuticke; 1911.Google Scholar
  10. Bobes J, Gonzales MP. Quality of life in schizophrenia. In: Katschnig H, Freeman H, Sartorius N, editors. Quality of life in mental disorders. Chichester: Wiley & Sons; 1997. p. 165–78.Google Scholar
  11. Bobes J, Garcia-Portilla P, Saiz PA, Bascaran T, Bousono M. Quality of life measures in schizophrenia. Eur Psychiatry. 2005;20:S313–7.CrossRefPubMedGoogle Scholar
  12. Bow-Thomas CC, Velligan DI, Miller AL, Olsen J. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Res. 1999;86:131–42.CrossRefPubMedGoogle Scholar
  13. Brooks R, Rabin R, De Charro F, editors. The measurement and valuation of health status using EQ-5D: a European perspective: evidence from the EuroQol BIOMED Research Programme. Springer Science & Business Media; Kluwer Academic Publishers - Dordrecht, Boston, London 2013.Google Scholar
  14. Caron J, Mercier C, Diaz P, Martin A. Socio-demographic and clinical predictors of quality of life in patients with schizophrenia or schizo-affective disorder. Psychiatry Res. 2005;137:203–13.CrossRefPubMedGoogle Scholar
  15. Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull. 2001;27:227–34.CrossRefPubMedGoogle Scholar
  16. Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33:1225–37.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, Rowland M, Schneider CK, Bloechl-Daum B. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10:495–506.CrossRefPubMedGoogle Scholar
  18. EMA. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf. Accessed 28 Aug 2015.
  19. Falissard B, Sapin C, Loze JY, Landsberg W, Hansen K. Defining the minimal clinically important difference (MCID) of the Heinrichs–Carpenter quality of life scale (QLS). Int J Methods Psychiatr Res. 2015. doi: 10.1002/mpr.1483. Published online: 4 AUG 2015.Google Scholar
  20. FDA. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed 28 Aug 2015.
  21. FDA. Guidance for industry and FDA staff: qualification process for drug development tools. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm230597.pdf. Accessed 28 Aug 2015.
  22. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ, WFSBP Task force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14:2–44.CrossRefPubMedGoogle Scholar
  23. Hayhurst KP, Massie JA, Dunn G, Lewis SW, Drake RJ. Validity of subjective versus objective quality of life assessment in people with schizophrenia. BMC Psychiatry. 2014;14:365.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409–16.CrossRefPubMedGoogle Scholar
  25. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388–98.CrossRefPubMedGoogle Scholar
  26. Ibáñez E, Giner J, Cervera S, Baca E, Bobes J, Leal C. El Cuestionario Sevilla de Calidad de Vida: propiedades psicométricas. Actas Luso Esp Neurol Psiquiatr. 1997;25 Suppl 2:24–31.Google Scholar
  27. Jääskeläinen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, Veijola J, Miettunen J. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39:1296–306.CrossRefPubMedGoogle Scholar
  28. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurts KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia – cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–86.CrossRefPubMedGoogle Scholar
  29. Karow A, Wittmann L, Schöttle D, Schäfer I, Lambert M. The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci. 2014;16:185–95.PubMedPubMedCentralGoogle Scholar
  30. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM, Naber D. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia. Schizophr Res. 2010;118:176–82.CrossRefPubMedGoogle Scholar
  31. Lehman AF, Ward NC, Linn LS. Chronic mental patients: the quality of life issue. Am J Psychiatry. 1982;10:1271–6.Google Scholar
  32. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009a;373:31–41.CrossRefPubMedGoogle Scholar
  33. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009b;14:429–47.CrossRefPubMedGoogle Scholar
  34. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMedGoogle Scholar
  35. Marquis P, Caron M, Emery MP, Scott JA, Arnould B, Acquadro C. The role of health-related quality of life data in the drug approval processes in the US and Europe. Pharm Med. 2011;25:147–60.CrossRefGoogle Scholar
  36. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:163–9.CrossRefPubMedPubMedCentralGoogle Scholar
  37. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10 Suppl 3:133–8.PubMedGoogle Scholar
  38. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia. CNS Drugs. 2009;23:649–59.PubMedGoogle Scholar
  39. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry. 2004;65:531–6.CrossRefPubMedGoogle Scholar
  40. Nilsson LL, Levander S. Quality of life and schizophrenia: no subjective differences among four living conditions. Nord J Psychiatry. 1998;52:277–83.CrossRefGoogle Scholar
  41. Oliver JPJ, Huxley PJ, Bridges K, Mohamad H. Quality of life and mental health services. London: Routledge; 1996.Google Scholar
  42. Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry. 2006;67:1397–403.CrossRefPubMedGoogle Scholar
  43. Pukrop R, Schlaak V, Möller-Leimkühler AM, Albus M, Czernik A, Klosterkötter J, Möller HJ. Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. Psychiatry Res. 2003;119:63–79.CrossRefPubMedGoogle Scholar
  44. Ritsner M, Modai I, Endicott J, Rivkin O, Nechamkin Y, Barak P, Goldin V, Ponizovsky A. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry. 2000;61:880–9.CrossRefPubMedGoogle Scholar
  45. Ritsner M, Ponizovsky A, Endicott J, Nechamkin Y, Rauchverger B, Silver H, Modai I. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol. 2002;12:31–8.CrossRefPubMedGoogle Scholar
  46. Ritsner MS, Lisker A, Arbitman M. Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factors. Qual Life Res. 2012;21:837–47.CrossRefPubMedGoogle Scholar
  47. Schneider K. Klinische Psychopathologie. Fünfte, neu bearbeitete Auflage der Beiträge zur Psychopathologie. Stuttgart: Georg Thieme Verlag; 1959.Google Scholar
  48. Schrank B, Bird V, Tylee A, Coggins T, Rashid T, Slade M. Conceptualising and measuring the well-being of people with psychosis: systematic review and narrative synthesis. Soc Sci Med. 2013;92:9–21.CrossRefPubMedGoogle Scholar
  49. Silverstein SM, Bellack AS. A scientific agenda for the concept of recovery as it applies to schizophrenia. Clin Psychol Rev. 2008;28:1108–24.CrossRefPubMedGoogle Scholar
  50. Siu CO, Harvey PD, Agid O, Waye M, Brambilla C, Wing-Kit C, Remington G. Insight and subjective measures of quality of life in chronic schizophrenia. Schizophr Res Cogn. 2.3 2015;127–132. (In press). http://dx.doi.org/10.1016/j.scog.2015.05.002.Google Scholar
  51. Speight J, Barendse SM. FDA guidance on patient reported outcomes. BMJ. 2010;340:c2921.CrossRefPubMedGoogle Scholar
  52. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RSE, McEvoy JP, Hsiao JK, Lieberman JA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007;164:428–36.CrossRefPubMedGoogle Scholar
  53. The Whoqol Group. The World Health Organization quality of life assessment (WHOQOL): development and general psychometric properties. Soc Sci Med. 1998;46:1569–85.CrossRefGoogle Scholar
  54. Voruganti LNP, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002;56:37–46.CrossRefPubMedGoogle Scholar
  55. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMedGoogle Scholar
  56. Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res. 2007;91(1):178–86.CrossRefPubMedGoogle Scholar
  57. Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V, Fitzpatrick R, Jenkinson C. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000;177:42–6.CrossRefPubMedGoogle Scholar
  58. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA. 1995;273:59–65.CrossRefPubMedGoogle Scholar
  59. Xiang YT, Chiu HF, Ungvari GS. Quality of life and mental health in Chinese culture. Curr Opin Psychiatry. 2010;23:43–7.CrossRefPubMedGoogle Scholar
  60. Xiang YT, Hou YZ, Yan F, Dixon LB, Ungvari GS, Dickerson F, Li WY, Li WX, Zhu YL, Chan SSM, Lee EHM, Chiu HFK, Chiu HF. Quality of life in community-dwelling patients with schizophrenia in China. J Nerv Ment Dis. 2012;200:584–7.CrossRefPubMedGoogle Scholar
  61. Zipursky RB, Agid O. Recovery, not progressive deterioration, should be the expectation in schizophrenia. World Psychiatry. 2015;14:94–6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Clinical DevelopmentLundbeckIssy-les-MoulineauxFrance
  2. 2.Global AnalyticsLundbeck A/SIssy-les-MoulineauxFrance

Personalised recommendations